{"id":"NCT01131676","sponsor":"Boehringer Ingelheim","briefTitle":"BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).","officialTitle":"A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2010-05-27","resultsPosted":"2016-05-16","lastUpdate":"2016-05-16"},"enrollment":7064,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"Placebo BI 10773 high dose","otherNames":[]},{"type":"DRUG","name":"BI 10773 high dose","otherNames":[]},{"type":"DRUG","name":"Placebo BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"Placebo BI 10773 low dose","otherNames":[]},{"type":"DRUG","name":"Placebo BI 10773 high dose","otherNames":[]}],"arms":[{"label":"BI 10773 low dose","type":"EXPERIMENTAL"},{"label":"BI 10773 high dose","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.","primaryOutcome":{"measure":"Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.","timeFrame":"From randomisation to individual end of observation, up to 4.6 years","effectByArm":[{"arm":"Placebo","deltaMin":12.1,"sd":null},{"arm":"Empagliflozin 10 mg","deltaMin":10.4,"sd":null},{"arm":"Empagliflozin 25 mg","deltaMin":10.5,"sd":null},{"arm":"All Empagliflozin","deltaMin":10.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"0.0382"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":615,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Colombia","Croatia","Czechia","Denmark","Estonia","France","Georgia","Greece","Hong Kong","Hungary","India","Indonesia","Israel","Italy","Japan","Malaysia","Mexico","Netherlands","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Russia","Singapore","South Africa","South Korea","Spain","Sri Lanka","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39026628","38992713","38770818","38419787","37449424","36700391","35472672","35166009","35005582","34752913","34558768","34463409","34325887","34129237","33754809","33243221","33217335","33050931","33004464","32994159","32893717","32618884","32485734","32369546","31495881","31295358","31163986","30885684","30767353","30586757","29777264","29693360","29203583","28904068","28666775","28386035","27299675","26378978","24943000"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":988,"n":2333},"commonTop":["Hypoglycaemia","Urinary tract infection","Hyperglycaemia","Nasopharyngitis","Upper respiratory tract infection"]}}